IPM Take
This is the kind of regulatory story that defines precision neurology. Huntington’s disease is inherited, devastating and still has no disease-modifying therapy. AMT-130 is not approved, and this is not a guarantee of access. But FDA accepting the three-year Phase I/II analysis as the primary basis for a BLA changes the temperature of the debate. For patients and families, the question is not abstract: can regulators move fast enough without asking people with a fatal disease to wait through impossible evidence standards?
Executive Summary
uniQure announced that FDA communicated during a Type B meeting that the three-year analysis from its Phase I/II AMT-130 programme can serve as the primary basis for a Biologics License Application seeking accelerated approval in Huntington’s disease. The company intends to submit the BLA in the third quarter of 2026. FDA also wants alignment on the confirmatory study design before submission, including possible use of a concurrent standard-of-care control instead of a sham procedure. Reuters separately reported the same regulatory opening. AMT-130 remains investigational and is not approved.
Why it matters
- Patients and families: Huntington’s is a disease where time is brutally concrete. A regulatory opening is not treatment access yet, but it matters when no disease-modifying option exists.
- Regulators: This is a test of accelerated approval in rare neurodegeneration, where conventional trial models can be slow, difficult and ethically contested.
- Clinicians and payers: If the filing moves forward, the next questions will be eligibility, specialist-centre readiness, neurosurgical delivery, long-term follow-up and durability of benefit.
Huntington’s disease does not give families the luxury of slow systems.
It is inherited. It is progressive. It affects movement, thinking, behaviour, work, relationships and identity. Many families know the disease before symptoms begin because they have watched it move through generations.
That is why the AMT-130 regulatory update matters.
uniQure says FDA has accepted the three-year Phase I/II analysis as the primary basis for a BLA seeking accelerated approval. The company also says FDA wants alignment on the confirmatory study design, including possible consideration of a concurrent standard-of-care control rather than a sham procedure.
This is not approval. It is not proof that access is coming. It is a regulatory opening.
But in Huntington’s disease, openings matter. AMT-130 is designed as a one-time gene therapy delivered directly to the brain. That makes it scientifically ambitious, operationally complex and politically sensitive. It also makes the evidence debate unavoidable: how should regulators evaluate a therapy that may alter disease biology, when large conventional trials are hard to run and slow to deliver?
For IPM, this story is not simply about one company. It is about whether precision neurology can build a credible access pathway for devastating genetic diseases. Patients need urgency. Regulators need confidence. Health systems need delivery infrastructure. Payers need durability data.
All four are needed. Speed without evidence is dangerous. Evidence without speed can become abandonment.
